Antiangiogenic Potential of Pomegranate Extracts
Created March 19, 2026
Updated on March 25, 2026
approved
Tags:
Item URL
Basic
Language
English
MainTitle
Antiangiogenic Potential of Pomegranate Extracts
Original ids
10.3390/plants13233350; 39683144; PMC11644541; 20.500.14243/516905; 11587/538507
Type
publication
bestAccessRight
OPEN
countries
Italy
Creator/Author
Full name
Riccardo Tornese, orcid: 0009-0002-8223-0346 ; Anna Montefusco, orcid: 0000-0002-1946-3887 ; Rocco Placì, orcid: 0009-0008-6131-2880 ; Teodoro Semeraro, orcid: 0000-0001-9239-9060 ; Miriana Durante, orcid: 0000-0002-1779-6426 ; Monica De Caroli, orcid: 0000-0001-8668-4711 ; Gianpiero Calabrese, orcid: 0000-0002-0137-4595 ; Anna Eleonora Caprifico, orcid: 0000-0002-2170-1063 ; Marcello Salvatore Lenucci, orcid: 0000-0002-6493-9549
Other
Description
<jats:p>Pomegranate (Punica granatum L.) has long been recognised for its rich antioxidant profile and potential health benefits. Recent research has expanded its therapeutic potential to include antiangiogenic properties, which are crucial for inhibiting the growth of tumours and other pathological conditions involving aberrant blood vessel formation. This review consolidates current findings on the antiangiogenic effects of pomegranate extracts. We explore the impact of pomegranate polyphenols, including ellagic acid, punicalagin, anthocyanins, punicic acid and bioactive polysaccharides on key angiogenesis-related pathways and endothelial cell function. Emphasis is placed on the effects of these extracts as phytocomplexes rather than isolated compounds. Additionally, we discuss the use of pomegranate by-products, such as peels and seeds, in the preparation of extracts within a green chemistry and circular economy framework, highlighting their value in enhancing extract efficacy and sustainability. By primarily reviewing in vitro and in vivo preclinical studies, we assess how these extracts modulate angiogenesis across various disease models and explore their potential as adjunctive therapies for cancer and other angiogenesis-driven disorders. This review also identifies existing knowledge gaps and proposes future research directions to fully elucidate the clinical utility of pomegranate extracts in therapeutic applications.</jats:p>
Publication Date
2024-11-29
Publisher
MDPI AG
Subjects
0301 basic medicine; 0303 health sciences; Botany; Review; angiogenesis; 03 medical and health sciences; extraction methods; ellagic acid; ellagitannins; QK1-989; punicalagin; <i>Punica granatum</i> L.; Punica granatum L, VEGF, angiogenesis, cancer, ellagic acid, ellagitannins, extraction methods, punicalagin, punicic acid, supplement; Punica granatum L.; angiogenesis; punicalagin; ellagic acid; ellagitannins; extraction methods; punicic acid; cancer; supplement; VEGF
isGreen
true
isInDiamondJournal
false
Publication
Name
Plants
Publication
Article
Starting page
3350
issnOnline
2223-7747
vol
13
Other Research Product
Detailed informations
system:type
Research Product
Management Info
Author
Last Updated
March 25, 2026, 10:37 (UTC)
Created
March 19, 2026, 00:06 (UTC)
Data and Resources
This item has no data
To access the resources you must log in
